Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic

• Verfasst von: Niederau, Claus [VerfasserIn]
• Verfasst von: Regenbogen, Claudia [VerfasserIn]
• Verfasst von: Fruehauf, Hans-Martin [VerfasserIn]
• Verfasst von: Merkel, Martin [VerfasserIn]
• Verfasst von: Ziagaki, Athanasia [VerfasserIn]
• Verfasst von: Mengel, Eugen [VerfasserIn]
• Verfasst von: Baerwald, Christoph [VerfasserIn]
• Verfasst von: Muschol, Nicole [VerfasserIn]
• Verfasst von: Staufner, Christian [VerfasserIn]
• Verfasst von: Lampe, Christina [VerfasserIn]
• Verfasst von: Gillessen, Anton [VerfasserIn]
• Verfasst von: Koehler, Jan Philipp [VerfasserIn]
• Verfasst von: Vom Dahl, Stephan [VerfasserIn]
• Titel: Management, vaccination status and COVID-19 morbidity of patients with Gaucher disease in Germany during the COVID-19 pandemic
• Paralleltitel: Behandlung, Impfstatus und COVID-19-Morbidität von Patienten mit Morbus Gaucher in Deutschland während der SARS-CoV2-Pandemie
• Verf.angabe: Claus Niederau, Claudia Regenbogen, Hans-Martin Fruehauf, Martin Merkel, Athanasia Ziagaki, Eugen Mengel, Christoph Baerwald, Nicole Muschol, Christian Staufner, Christina Lampe, Anton Gillessen, Jan Philipp Koehler, Stephan vom Dahl
• E-Jahr: 2023
• Jahr: 10.01.2023
• Umfang: 6 S.
• Fussnoten: Gesehen am 23.06.2023
• Titel Quelle: Enthalten in: Zeitschrift für Gastroenterologie
• Ort Quelle: Stuttgart [u.a.] : Thieme, 1997
• Jahr Quelle: 2023
• Band/Heft Quelle: 61(2023), 04 vom: Jan., Seite 375-380
• ISSN Quelle: 1439-7803
• DOI: doi:10.1055/a-1821-9009
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1850912688

Abstract

Background: Continuation of standard management of Gaucher disease (GD) has been challenging during the COVID-19 pandemic, resulting in infrequent/missed infusions and follow-up appointments. Little data are available on the consequences of these changes and on the SARS-CoV-2 vaccinations in German GD patients. Methods: A survey with 22 questions about GD management during the pandemic was sent to 19 German Gaucher centres. It was answered by 11/19 centres caring for 257 GD patients (almost ¾ of the German GD population); 245 patients had type 1 and 12 had type 3 GD; 240 were ≥ 18 years old. Results: Monitoring intervals were prolonged in 8/11 centres from a median of 9 to 12 months. Enzyme replacement therapy (ERT) was changed to home ERT in 4 patients and substituted by oral substrate reduction therapy (SRT) in 6 patients. From March 2020 to October 2021, no serious complications of GD were documented. Only 4 SARS-CoV-2 infections were reported (1.6%). Two infections were asymptomatic and two mild; all occurred in adult type 1, non-splenectomized patients on ERT. Vaccination rate in adult GD was 79.5% (95.3% mRNA vaccines). Serious vaccination complications were not reported. Conclusions: The COVID-19 pandemic has lowered the threshold for switching from practice- or hospital-based ERT to home therapy or to SRT. No major GD complication was documented during the pandemic. Infection rate with SARS-CoV-2 in GD may rather be lower than expected, and its severity is mild. Vaccination rates are high in GD patients and vaccination was well tolerated.